Kythera Biophrarma (KYTH) Tops Q1 EPS by 236c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update
May 7, 2015 4:06 PM EDTWESTLAKE VILLAGE, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) today reported financial results for the first quarter of 2015, and provided an update on recent accomplishments.
KYTHERA recently achieved our most significant milestone to date, that of receiving FDA approval of KYBELLA, which is the first and only FDA approved injectable drug that contours and improves the appearance of submental fullness, said Keith Leonard, KYTHERAs President and CEO. This approval came after we received a unanimous (17-0) recommendation for approval for KYBELLA from the FDAs Dermatologic and Ophthalmic Drugs... More
